Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Armeanu Ebinger, Sorin ^a   Hoh, Alexander ^a   Wenz, Julia ^a   Fuchs, Joerg ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

T cells; EpCAM (CD326); Hepatoblastoma; Immunotherapy; PBMC; Therapeutic antibodies

Indexed keywords

CD45 ANTIGEN; CISPLATIN; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; ZOLEDRONIC ACID;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORPHOLOGY; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LIVER CARCINOGENESIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TUMOR XENOGRAFT; UPREGULATION;

EID: 84886945370     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22620     Document Type: Article

References (42)

1. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967; 20:396-422; PMID:4290059; http:// dx.doi.org/10.1002/1097-0142(1967)20:3<396::AIDCNCR2820200308> 3.0.CO;2-O.
2. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002; 20:2789-97; PMID:12065555; http:// dx.doi.org/10.1200/JCO.2002.06.155.
3. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983; 14:512-37; PMID:6303939; http://dx.doi.org/10.1016/S0046-8177(83)80005-7.
4. Czauderna P, Otte JB, Roebuck DJ, von Schweinitz D, Plaschkes J. Surgical treatment of hepatoblastoma in children. Pediatr Radiol 2006; 36:187-91; PMID:16404555; http://dx.doi.org/10.1007/s00247-005-0067-0.
5. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008; 13:812-20; PMID:18644850; http://dx.doi.org/10.1634/theoncologist.2008-0011.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857.
7. Perilongo G, Otte JB. Autologous peripheral blood stem-cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation-- a valid therapeutic option or just too much? Pediatr Transplant 2009; 13:148-9; PMID:18764910; http://dx.doi.org/10.1111/j.1399-3046.2008.01015.x.
8. Ruck P, Wichert G, Handgretinger R, Kaiserling E. Ep-CAM in malignant liver tumours. J Pathol 2000; 191:102-3; PMID:10767726; http://dx.doi.org/10.1002/(SICI)1096-9896(200005)191:1<102::AIDPATH542>3.0.CO;2-X.
9. Ward SC, Thung SN, Lim KH, Tran TT, Hong TK, Hoang PL, et al. Hepatic progenitor cells in liver cancers from Asian children. Liver Int 2010; 30:102-11; PMID:19793197; http://dx.doi.org/10.1111/j.1478-3231.2009.02126.x.
10. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000; 356:1981-2; PMID:11130529; http://dx.doi.org/10.1016/S0140-6736(00)03312-2.
11. Prince S, Zeidman A, Dekel Y, Ram E, Koren R. Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables. Am J Clin Pathol 2008; 129:424-9; PMID:18285265; http://dx.doi.org/10.1309/ H8JEEAEB69J3KYND.
12. Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol 2010; 203:582, e1-7; PMID:20870202; http://dx.doi. org/10.1016/j.ajog.2010.07.041.
13. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68:1451-61; PMID:18316609; http://dx.doi.org/10.1158/0008-5472.CAN-07-6013.
14. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 2012; 38:68-75; PMID:21576002.
15. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004; 23:5748-58; PMID:15195135; http://dx.doi. org/10.1038/sj.onc.1207610.
16. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007; 96:417-23; PMID:17211480; http://dx.doi.org/10.1038/ sj.bjc.6603494.
17. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69:5627-9; PMID:19584271; http://dx.doi. org/10.1158/0008-5472.CAN-09-0654.
18. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975-1026; PMID:10837080; http://dx.doi.org/10.1146/annurev. immunol.18.1.975.
19. Meraviglia S, El Daker S, Dieli F, Martini F, Martino A. ?d T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011:587315; PMID:21253470; http://dx.doi.org/10.1155/2011/587315.
20. Urban EM, Chapoval AI, Pauza CD. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin Dev Immunol 2010; 2010:732893; PMID:20396597; http://dx.doi. org/10.1155/2010/732893.
21. Morita CT, Lee HK, Leslie DS, Tanaka Y, Bukowski JF, Marker-Hermann E. Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells. Microbes Infect 1999; 1:175-86; PMID:10594981; http://dx.doi.org/10.1016/S1286-4579(99)80032-X.
22. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 2005; 175:2144-51; PMID:16081780.
23. Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10:842-56; PMID:19016372; http://dx.doi.org/10.1080/14653240802419328.
24. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005; 174:1338-47; PMID:15661891.
25. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14:471-84; PMID:19061838; http://dx.doi. org/10.1016/j.ccr.2008.11.002.
26. Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28:2584-90; PMID:20406943; http://dx.doi.org/10.1200/ JCO.2009.22.4857.
27. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010; 70:7830-40; PMID:20940408; http:// dx.doi.org/10.1158/0008-5472.CAN-10-0833.
28. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67:10831-9; PMID:18006828; http://dx.doi.org/10.1158/0008-5472.CAN-07-0908.
29. Petsch S, Gires O, Rüttinger D, Denzel S, Lippold S, Baeuerle PA, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 2011; 3:31-7; PMID:21107020; http://dx.doi. org/10.4161/mabs.3.1.14193.
30. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214:441-53; PMID:19157637; http://dx.doi.org/10.1016/j.imbio.2008.11.014.
31. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763-71; PMID:16360021; http://dx.doi. org/10.1016/j.molimm.2005.03.007.
32. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18:465-74; PMID:22096026; http://dx.doi.org/10.1158/1078-0432.CCR-11-1270.
33. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/ CD3-bispecific antibody engaging human T cells. PLoS One 2010; 5:e13474; PMID:20976159; http:// dx.doi.org/10.1371/journal.pone.0013474.
34. Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu- Ebinger S, Kluba T, et al. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer 2010; 10:501; PMID:20858262; http://dx.doi. org/10.1186/1471-2407-10-501.
35. Inaba H, Handgretinger R, Furman W, Hale G, Leung W. Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer 2006; 46:501-5; PMID:15806543; http://dx.doi.org/10.1002/ pbc.20404.
36. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996; 74:809-18; PMID:8606490.
37. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976; 67:1-10; PMID:57894.
38. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. Development of a drug resistance model for hepatoblastoma. Int J Oncol 2011; 38:447-54; PMID:21132272.
39. δ T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int 2012; In press; PMID:23088518.
40. Ebinger M, Witte KE, Ahlers J, Schäfer I, André M, Kerst G, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res 2010; 34:1139-42; PMID:20378168; http://dx.doi. org/10.1016/j.leukres.2010.03.023.
41. Ellerkamp V, Armeanu-Ebinger S, Wenz J, Warmann SW, Schäfer J, Ruck P, et al. Successful establishment of an orthotopic hepatoblastoma in vivo model in NOD/ LtSz-scid IL2Rγnull mice. PLoS One 2011; 6:e23419; PMID:21853130; http://dx.doi.org/10.1371/journal. pone.0023419.
42. Lieber J, Eicher C, Wenz J, Kirchner B, Warmann SW, Fuchs J, et al. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 2011; 11:362; PMID:21854558; http://dx.doi.org/10.1186/1471-2407-11-362.